CSF A β40 and P-tau181 might differentiate atypical from typical AD phenotypes: preliminary evidence

Conclusions. The present study delivers promising, albeit preliminary, evidence on the utility of Aβ40 and P-tau181 CSF biomarkers in diff erentiating atypical from typical Aβ42/40-confirmed AD phenotypes, prompting further research and confirmation on larger cohorts.

Source: Neurodegenerative Diseases - September 15, 2022 Category: Neurology Source Type: research